Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase

Akira Abe, Lois J Arend, Lihsueh Lee, Clifford Lingwood, Roscoe O. Brady, James A. Shayman

Research output: Contribution to journalArticle

Abstract

Background. Fabry disease is an inherited X-linked disorder resulting in the loss of activity of the lysosomal hydrolase α-galactosidase A and causing the clinical manifestations of renal failure, cerebral vascular disease, and myocardial infarction. The phenotypic expression of this disorder is manifest by the accumulation of glycosphingolipids containing α- galactosyl linkages, most prominently globotriaosylceramide. Methods. Based on quantitative structure activity studies, we recently reported two newly designed glucosylceramide synthase inhibitors based on 1-phenyl-2- palmitoylamino-3-pyrrolidino-1-propanol (P4). These inhibitors, 4'-hydroxy-P4 and ethylenedioxy-P4, were evaluated for their ability to deplete globotriaosylceramide and other glucosylceramide-based lipids in Fabry lymphocytes and were compared with N-butyldeoxynojirimycin, another reported glucosylceramide synthase inhibitor. Results. Concentrations as low as 10 nmol/L of 4'-hydroxy-P4 and ethylenedioxy-P4 resulted in 70 and 80% depletion, respectively, of globotriaosylceramide, with maximal depletion occurring at three days of treatment. There was no impairment of cell growth. In contrast, N-butyldeoxynojirimycin only minimally lowered globotriaosylceramide levels, even at concentrations as high as 10 μmol/L. Globotriaosylceramide depletion was confirmed by the loss of binding of FITC- conjugated verotoxin B subunit to the lymphoblasts. Conclusions. These findings suggest that selective glucosylceramide synthase inhibitors are highly effective in the depletion of globotriaosylceramide from Fabry cell lines. We suggest that these compounds have potential therapeutic utility in the treatment of Fabry disease.

Original languageEnglish (US)
Pages (from-to)446-454
Number of pages9
JournalKidney International
Volume57
Issue number2
DOIs
StatePublished - 2000

Fingerprint

ceramide glucosyltransferase
Fabry Disease
Glycosphingolipids
Galactosidases
Shiga Toxins
Glucosylceramides
Fluorescein-5-isothiocyanate
Hydrolases
Vascular Diseases
Renal Insufficiency
globotriaosylceramide
Myocardial Infarction
Lymphocytes
Lipids
Cell Line

Keywords

  • α-galactosidase A
  • Fabry cell lines
  • Globotriaosylceramide
  • Verotoxin
  • X-linked disorder

ASJC Scopus subject areas

  • Nephrology

Cite this

Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase. / Abe, Akira; Arend, Lois J; Lee, Lihsueh; Lingwood, Clifford; Brady, Roscoe O.; Shayman, James A.

In: Kidney International, Vol. 57, No. 2, 2000, p. 446-454.

Research output: Contribution to journalArticle

Abe, Akira ; Arend, Lois J ; Lee, Lihsueh ; Lingwood, Clifford ; Brady, Roscoe O. ; Shayman, James A. / Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase. In: Kidney International. 2000 ; Vol. 57, No. 2. pp. 446-454.
@article{d58df7fd0823454598ef40e5318f7f87,
title = "Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase",
abstract = "Background. Fabry disease is an inherited X-linked disorder resulting in the loss of activity of the lysosomal hydrolase α-galactosidase A and causing the clinical manifestations of renal failure, cerebral vascular disease, and myocardial infarction. The phenotypic expression of this disorder is manifest by the accumulation of glycosphingolipids containing α- galactosyl linkages, most prominently globotriaosylceramide. Methods. Based on quantitative structure activity studies, we recently reported two newly designed glucosylceramide synthase inhibitors based on 1-phenyl-2- palmitoylamino-3-pyrrolidino-1-propanol (P4). These inhibitors, 4'-hydroxy-P4 and ethylenedioxy-P4, were evaluated for their ability to deplete globotriaosylceramide and other glucosylceramide-based lipids in Fabry lymphocytes and were compared with N-butyldeoxynojirimycin, another reported glucosylceramide synthase inhibitor. Results. Concentrations as low as 10 nmol/L of 4'-hydroxy-P4 and ethylenedioxy-P4 resulted in 70 and 80{\%} depletion, respectively, of globotriaosylceramide, with maximal depletion occurring at three days of treatment. There was no impairment of cell growth. In contrast, N-butyldeoxynojirimycin only minimally lowered globotriaosylceramide levels, even at concentrations as high as 10 μmol/L. Globotriaosylceramide depletion was confirmed by the loss of binding of FITC- conjugated verotoxin B subunit to the lymphoblasts. Conclusions. These findings suggest that selective glucosylceramide synthase inhibitors are highly effective in the depletion of globotriaosylceramide from Fabry cell lines. We suggest that these compounds have potential therapeutic utility in the treatment of Fabry disease.",
keywords = "α-galactosidase A, Fabry cell lines, Globotriaosylceramide, Verotoxin, X-linked disorder",
author = "Akira Abe and Arend, {Lois J} and Lihsueh Lee and Clifford Lingwood and Brady, {Roscoe O.} and Shayman, {James A.}",
year = "2000",
doi = "10.1046/j.1523-1755.2000.00864.x",
language = "English (US)",
volume = "57",
pages = "446--454",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase

AU - Abe, Akira

AU - Arend, Lois J

AU - Lee, Lihsueh

AU - Lingwood, Clifford

AU - Brady, Roscoe O.

AU - Shayman, James A.

PY - 2000

Y1 - 2000

N2 - Background. Fabry disease is an inherited X-linked disorder resulting in the loss of activity of the lysosomal hydrolase α-galactosidase A and causing the clinical manifestations of renal failure, cerebral vascular disease, and myocardial infarction. The phenotypic expression of this disorder is manifest by the accumulation of glycosphingolipids containing α- galactosyl linkages, most prominently globotriaosylceramide. Methods. Based on quantitative structure activity studies, we recently reported two newly designed glucosylceramide synthase inhibitors based on 1-phenyl-2- palmitoylamino-3-pyrrolidino-1-propanol (P4). These inhibitors, 4'-hydroxy-P4 and ethylenedioxy-P4, were evaluated for their ability to deplete globotriaosylceramide and other glucosylceramide-based lipids in Fabry lymphocytes and were compared with N-butyldeoxynojirimycin, another reported glucosylceramide synthase inhibitor. Results. Concentrations as low as 10 nmol/L of 4'-hydroxy-P4 and ethylenedioxy-P4 resulted in 70 and 80% depletion, respectively, of globotriaosylceramide, with maximal depletion occurring at three days of treatment. There was no impairment of cell growth. In contrast, N-butyldeoxynojirimycin only minimally lowered globotriaosylceramide levels, even at concentrations as high as 10 μmol/L. Globotriaosylceramide depletion was confirmed by the loss of binding of FITC- conjugated verotoxin B subunit to the lymphoblasts. Conclusions. These findings suggest that selective glucosylceramide synthase inhibitors are highly effective in the depletion of globotriaosylceramide from Fabry cell lines. We suggest that these compounds have potential therapeutic utility in the treatment of Fabry disease.

AB - Background. Fabry disease is an inherited X-linked disorder resulting in the loss of activity of the lysosomal hydrolase α-galactosidase A and causing the clinical manifestations of renal failure, cerebral vascular disease, and myocardial infarction. The phenotypic expression of this disorder is manifest by the accumulation of glycosphingolipids containing α- galactosyl linkages, most prominently globotriaosylceramide. Methods. Based on quantitative structure activity studies, we recently reported two newly designed glucosylceramide synthase inhibitors based on 1-phenyl-2- palmitoylamino-3-pyrrolidino-1-propanol (P4). These inhibitors, 4'-hydroxy-P4 and ethylenedioxy-P4, were evaluated for their ability to deplete globotriaosylceramide and other glucosylceramide-based lipids in Fabry lymphocytes and were compared with N-butyldeoxynojirimycin, another reported glucosylceramide synthase inhibitor. Results. Concentrations as low as 10 nmol/L of 4'-hydroxy-P4 and ethylenedioxy-P4 resulted in 70 and 80% depletion, respectively, of globotriaosylceramide, with maximal depletion occurring at three days of treatment. There was no impairment of cell growth. In contrast, N-butyldeoxynojirimycin only minimally lowered globotriaosylceramide levels, even at concentrations as high as 10 μmol/L. Globotriaosylceramide depletion was confirmed by the loss of binding of FITC- conjugated verotoxin B subunit to the lymphoblasts. Conclusions. These findings suggest that selective glucosylceramide synthase inhibitors are highly effective in the depletion of globotriaosylceramide from Fabry cell lines. We suggest that these compounds have potential therapeutic utility in the treatment of Fabry disease.

KW - α-galactosidase A

KW - Fabry cell lines

KW - Globotriaosylceramide

KW - Verotoxin

KW - X-linked disorder

UR - http://www.scopus.com/inward/record.url?scp=0033930125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033930125&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1755.2000.00864.x

DO - 10.1046/j.1523-1755.2000.00864.x

M3 - Article

C2 - 10652021

AN - SCOPUS:0033930125

VL - 57

SP - 446

EP - 454

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 2

ER -